Autolus Therapeutics (AUTL) Net Income towards Common Stockholders (2017 - 2025)
Historic Net Income towards Common Stockholders for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$79.1 million.
- Autolus Therapeutics' Net Income towards Common Stockholders rose 362.51% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 1680.99%. This contributed to the annual value of -$220.7 million for FY2024, which is 589.25% down from last year.
- According to the latest figures from Q3 2025, Autolus Therapeutics' Net Income towards Common Stockholders is -$79.1 million, which was up 362.51% from -$47.9 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$6.8 million for Q4 2021, and its period low was -$34.0 billion during Q3 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$1.8 billion, with a median of -$45.6 million in 2023.
- Within the past 5 years, the most significant YoY rise in Autolus Therapeutics' Net Income towards Common Stockholders was 9998.97% (2021), while the steepest drop was 9099205.41% (2021).
- Autolus Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$6.8 million in 2021, then tumbled by 298.16% to -$27.0 million in 2022, then crashed by 186.04% to -$77.2 million in 2023, then soared by 64.23% to -$27.6 million in 2024, then crashed by 186.6% to -$79.1 million in 2025.
- Its last three reported values are -$79.1 million in Q3 2025, -$47.9 million for Q2 2025, and -$70.2 million during Q1 2025.